The fourth IACT review meeting took place on October 25-26, 2017 in London, United Kingdom....
Leadartis is part of the Genoma España´s Technology Portfolio
01-02-2008
In 2008 LeadArtis signed an agreement with Genoma España, and it has been incorporated to its Technology Portfolio (www.gen-es.com.es). The agreement supported the creation of the company and represented an infusion of resources to finance LeadArtis´start-up activities.
- « first
- ‹ previous
- 1
- 2
- 3
- 4
Latest News
|
LeadArtis participates in the fourth Immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) meeting in London (UK)
31-10-2017
|
LeadArtis discloses ATTACK, a novel bispecific T cell-recruiting antibody approach for cancer immunotherapy
15-01-2018
LeadArtis´scientists, in collaboration with other prime... |
Leadartis successfully accomplishes the TERET project
07-04-2017
Leadartis is proud to announce the successful conclusion of the TERET (New Treatments for... |
